Anteris Technologies Global Corp. — AGM Information 2024

Apr 9, 2024

==> picture [192 x 28] intentionally omitted <==

ASX ANNOUNCEMENT

10 April 2024

Notice of Annual General Meeting and Director Nominations

Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) advises that in accordance with ASX Listing Rule 3.13.1, the Company’s Annual General Meeting (“AGM”) will be held at 10:00 a.m. AEST on Wednesday 29 May 2024.

One item of business at the AGM will be the election of Directors. In accordance with clause 9.5 (c) and (d) of Anteris Technologies Ltd’s Constitution, the closing date for the receipt of nominations is Monday 15 April 2024. Nominations must be received at Anteris Technologies Ltd’s registered office no later than 5 p.m. AEST on the closing date.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company’s lead product, DurAVR[TM] , is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR[TM] THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR[TM] THV is made using ADAPT[®] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR[TM] Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR[TM] THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

==> picture [41 x 40] intentionally omitted <==

REGISTERED OFFICE Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD 4066 Australia

T: +61 1300 550 310 info.au@anteristech.com anteristech.com

BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

==> picture [195 x 28] intentionally omitted <==

Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Investor Relations investors@anteristech.com Anteris Technologies Ltd +61 1300 550 310 | +61 7 3152 3200

Investor Relations (US) Malini Chatterjee, Ph.D. Managing Director Blueprint Life Science Group +1 917 330 4269

Website www.anteristech.com Twitter @AnterisTech Facebook www.facebook.com/AnterisTechnologies LinkedIn https://www.linkedin.com/company/anteristech

==> picture [41 x 40] intentionally omitted <==